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Abstract Since D-amino acids were identified in mam-
mals, D-serine has been one of the most extensively studied
‘‘unnatural amino acids’’. This brain-enriched transmitter-
like molecule plays a pivotal role in the human central
nervous system by modulating the activity of NMDA
receptors. Physiological levels of D-serine are required for
normal brain development and function; thus, any altera-
tions in neuromodulator concentrations might result in
NMDA receptor dysfunction, which is known to be
involved in several pathological conditions, including
neurodegeneration(s), epilepsy, schizophrenia, and bipolar
disorder. In the brain, the concentration of D-serine stored
in cells is defined by the activity of two enzymes: serine
racemase (responsible for both the synthesis and degrada-
tion) and D-amino acid oxidase (which catalyzes D-serine
degradation). Both enzymes emerged recently as new
potential therapeutic targets for NMDA receptor-related
diseases. In this review we have focused on human
D-amino acid oxidase and provide an extensive overview of
the biochemical and structural properties of this flavopro-
tein and their functional significance. Furthermore, we
discuss the mechanisms involved in modulating enzyme
activity and stability with the aim to substantiate the piv-
otal role of D-amino acid oxidase in brain D-serine metab-
olism in physiological and pathological conditions and to
highlight its great significance for novel drug design/
development.
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PTS1 Peroxisomal targeting signal 1
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Tm Melting temperature
S. Sacchi (&)  L. Caldinelli  P. Cappelletti  L. Pollegioni 
G. Molla
Dipartimento di Biotecnologie e Scienze della Vita,
Universita` degli studi dell’Insubria,
via J.H. Dunant 3, 21100 Varese, Italy
e-mail: silvia.sacchi@uninsubria.it
S. Sacchi  L. Caldinelli  L. Pollegioni  G. Molla
The Protein Factory, Centro Interuniversitario di Biotecnologie
Proteiche, Politecnico di Milano, ICRM CNR Milano,
Universita` degli Studi dell’Insubria, Varese, Italy
123
Amino Acids (2012) 43:1833–1850
DOI 10.1007/s00726-012-1345-4
Introduction
The flavoenzyme D-amino acid oxidase (DAAO, EC 1.4.3.3)
is the only enzyme which has been proven to catalyze the
strictly specific oxidative deamination of neutral D-amino
acids. It was first discovered in the porcine kidney by Krebs
(1935) and since then has been extensively studied as a
model of FAD-dependent oxidase. DAAO has a broad sub-
strate specificity and metabolizes a number of neutral,
hydrophobic, polar, and basic D-amino acids (Pilone et al.
1989; Curti et al. 1992; Pilone 2000; Pollegioni et al. 2007a,
b). The different substrates are oxidized through the con-
comitant reduction of the FAD cofactor to give the corre-
sponding imino acids and hydrogen peroxide, produced upon
flavin reoxidation on molecular oxygen; subsequently, the
imino acids nonenzymatically hydrolyze to a-keto acids and
ammonia (Fig. 1a).
Putative DAAO genes have been identified in all king-
doms (plants representing the main exception) and DAAO
from a variety of sources, ranging from microorganisms to
mammals, have been purified and characterized (Pollegioni
et al. 2007a). Several DAAO protein sequence regions are
highly conserved across species, including residues that
constitute the active site and those interacting with FAD,
see below (Pollegioni et al. 2007b). All known DAAOs
possess a C-terminal PTS1 sequence for peroxisomal tar-
geting. Indeed, owing to this localization the cytotoxic
product hydrogen peroxide can be efficiently removed.
DAAO plays diverse roles in different organisms: its
main function in microorganisms is to make D-amino
acids—via enzymatic oxidation—available for cell
metabolism. However, several specific functions in nema-
todes, insects and lower vertebrates have also been pro-
posed (Pollegioni et al. 2007a; Saitoh et al. 2012). In
mammals DAAO is mainly present in kidney and liver
(although it is not present in the mouse liver) (Konno et al.
1997) and, unexpectedly, it is enriched in the brain. His-
torically, endogenous D-amino acids were considered to be
absent in higher animals. In fact, although DAAO enzyme
activity was detected in mammal brains over 40 years ago
(Neims et al. 1966; Arnold et al. 1979), its role remained
enigmatic until D-amino acids (including D-alanine, D-ser-
ine, D-leucine and D-proline) were discovered in brain tis-
sues. Among them D-serine is by far the most abundant
(Nagata et al. 1992, 1994; Hashimoto et al. 1993; Hamase
et al. 1997; Inoue et al. 2000; Morikawa et al. 2003; Song
et al. 2008).
D-Serine: synthesis and role
D-Serine, an atypical signaling molecule, is synthesized
from L-serine by the PLP-dependent enzyme serine race-
mase (EC 5.1.1.18, SR, also present in the brain) (Wolos-
ker et al. 1999a, b; Conti et al. 2011) and is presumably
degraded by both SR, which also catalyzes the a,b-elimi-
nation of water from L- and D-serine (Foltyn et al. 2005),
and DAAO (Pollegioni and Sacchi 2010). D-Serine binds to
the ‘‘strychnine-insensitive glycine modulatory site’’ of the
N-methyl-D-aspartate type glutamate receptor (NMDAR)
(Mothet et al. 2000); thus, it plays a key role as a coagonist
of this excitatory receptor, which is critically involved in
brain development, neuronal cell migration, and plasticity
as well as in learning, memory, and excitotoxicity (Wo-
losker et al. 1999b; Foltyn et al. 2005; Mothet et al. 2000;
Snyder and Kim 2000; Martineau et al. 2006; Wolosker
et al. 2008). Interestingly, the distribution pattern of DAAO
gene and protein expression in the central nervous system
(CNS) is inversely correlated with D-serine content and
distribution (Horiike et al. 1994). Brain DAAO activity can
be detected and increases rapidly in the cerebellum, pons,
Fig. 1 a Scheme of the oxidative deamination of D-serine catalyzed
by DAAO. The hydride transfer of the a-proton of D-serine to the
oxidized FAD cofactor (DAAOox) yields imino-serine and reduced
flavin (DAAOred). The imino acid is subsequently nonenzymatically
hydrolyzed to hydroxypyruvate and ammonia, while the reduced
flavin is reoxidized by molecular oxygen, producing hydrogen
peroxide. b Role of hDAAO and pLG72 on D-serine bioavailability
at glutamatergic synapses: pLG72 modulates the amount of active
hDAAO acting on the stability of the holoenzyme. Under pathological
conditions, the supposed lower expression level of pLG72 would
result in an overactivation of hDAAO and a consequent decrease in D-
serine cellular concentration
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and medulla oblongata of rodents around postnatal day 10
(Weimar and Neims 1977) when D-serine concentration
starts to significantly decrease in the same areas/regions
(Hashimoto et al. 1995). Based on these findings, it was
proposed that DAAO might physiologically affect
NMDAR function by modulating D-serine cellular storage/
turnover and thus, indirectly, its availability at the synapses
(Fig. 1b). Although the observation that, at the cellular
level, exogenously applied yeast DAAO reduces NMDAR-
mediated currents supports this notion (Mothet et al. 2000;
Stevens et al. 2003; Panatier et al. 2006), the biological
relevance of DAAO has occasionally been questioned
because of the modest affinity of the mammalian flavoen-
zyme for its substrates (in the millimolar range, see below)
(Molla et al. 2006a; Pollegioni and Sacchi 2010) and the
low D-amino acids concentration in the brain. Indirect data
from studies performed in transgenic animals strikingly
substantiate the crucial physiological role of the flavoen-
zyme: in ddY/DAAO-/- mice DAAO activity is lost due to
an inactivating point mutation (Gly181Arg) (Konno and
Yasumura 1983; Sasaki et al. 1992) and a substantial
increase (several fold) in the concentrations of D-serine and
other D-amino acids is detected. ddY/DAAO-/- mice dis-
play behavioral phenotypes consistent with altered
NMDAR signaling, including decreased stereotypy and
ataxia elicited by MK-801 (Almond et al. 2006; Hashimoto
et al. 2005) and enhanced spatial learning and long-term
potentiation (LTP) in the hippocampus (Maekawa et al.
2005). Furthermore, oral or systemic administration of
DAAO inhibitors to normal rodents elevated central
D-serine levels (Adage et al. 2008; Duplantier et al. 2009)
and increased NMDAR-mediated function (Verrall et al.
2010). These findings support a major role for DAAO in
D-amino acid—in particular D-serine—metabolism. How-
ever, the recent observation that SR is predominantly
expressed in neurons (which release D-serine upon mem-
brane depolarization) (Kartvelishvily et al. 2006; Rosen-
berg et al. 2010) and poorly expressed in astrocytes (the
cells containing the highest amount of D-serine in most
brain regions) (Schell et al. 1997; Kartvelishvily et al.
2006; Puyal et al. 2006; Williams et al. 2006; Ding et al.
2011) argues against its role as the main D-serine-degrading
enzyme, at least in the latter cell type.
Apart from NMDAR modulation, D-serine also antago-
nizes AMPA glutamate receptors (Gong et al. 2007), sug-
gesting that this neuromodulator (and its degrading
enzyme) could be involved in both positive and negative
modulatory effects at glutamatergic synapses. D-Serine is
also an endogenous ligand of the ionotropic glutamate-like
receptor GluRd2, which is important in cerebellar devel-
opment and plasticity (Hansen et al. 2009). Moreover,
D-serine may antagonize NR1/NR3A or NR1/NR3B
receptors (which are insensitive to glutamate and activated
by glycine) and thus modulate glycinergic transmission
(Chatterton et al. 2002; Takarada et al. 2009). On the other
hand, DAAO might be involved in the metabolism of both
D-proline, which does not act at NMDARs but can activate
glycine receptors (Hamasu et al. 2008), and D-leucine, a
potent regulator of the blood–brain barrier enkephalin
transport system (Banks and Kastin 1991).
DAAO brain localization
DAAO is widely present in the adult human CNS, but its
distribution in terms of brain regions, cell types, and sub-
cellular compartments is still under debate, in particular
concerning the levels of enzyme expression and activity.
Although a regional heterogeneity has been observed,
DAAO is generally considered to be a hindbrain enzyme
that is enriched in the cerebellum and in the brainstem
(Horiike et al. 1994). In agreement with previous studies in
rodents (Schell et al. 1997; Moreno et al. 1999; Wolosker
et al. 2008), DAAO expression and activity were robustly
detected in the cerebellum in human brain (Kapoor et al.
2006; Verrall et al. 2007), particularly in Bergmann glia
(Verrall et al. 2007) (Fig. 2a–d). DAAO distribution in the
human forebrain is less clear. Notwithstanding the barely
measurable levels of enzyme activity, a consistent amount
of DAAO mRNA and protein has been highlighted.
Bendikov et al. (2007) detected robust levels of this fla-
voprotein in the parietal lobe, and Verrall et al. (2007)
confirmed that DAAO protein is unequivocally expressed
in human cerebral cortex and hippocampus, also showing
that its mRNA is mainly distributed within neurons and to a
small degree in glia. Since it was not feasible to detect the
protein by Western blot analysis, they raised the intriguing
issue of a regional heterogeneity in DAAO antigenicity,
possibly due to differences in post-translational modifica-
tions (Verrall et al. 2007). Flavoenzyme expression was
further confirmed in the prefrontal cortex by immunolo-
calization and immunoprecipitation studies performed in
our laboratory (Sacchi et al. 2008); DAAO seems to be
present essentially in glial cells. We hypothesized that
DAAO activity could not be detected by the commonly
used assay in the forebrain because some kind of negative
effector (a small ligand or an inactivating protein) is
present along with the enzyme, downregulating its—
already low—activity (Molla et al. 2006a).
Subcellular localization
DAAO subcellular distribution, in particular concerning
the way by which it might exert its putative physiological
function as a peroxisomal enzyme (Fig. 2e, f), represents
an additional point for discussion. It is conceivable that
D-serine could access the peroxisomes through a not yet
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identified membrane transport mechanism; otherwise, an
active form of DAAO might be present in the cytosol, thus
directly consuming D-serine from cytosolic storage.
Interestingly, the presence of an extraperoxisomally active
DAAO has been reported both in glial cells (Sacchi et al.
2008, 2011) and neurons (Popiolek et al. 2011). The
Fig. 2 Human DAAO regional and cellular distribution. a In the
prefrontal cortex, hDAAO immunoreactivity is localized essentially
in the gray matter (gm), compared to the unstained white matter
(wm); b in the same brain region the immunorecognition signal
corresponding to the flavoprotein is mainly evident in pyramidal
neurons, which are labeled throughout their cell bodies (asterisk); c in
the cerebellum hDAAO is mainly distributed in the Purkinje cell layer
(pcl) with moderate staining observed in the molecular layer (ml),
granule cell layer (gcl), and white matter (wm); d in this region,
Bergmann glia cells in the Purkinje cell layer (pcl) are strongly
immunopositive (arrows), whereas Purkinje cells are unstained
(asterisk); in the molecular layer (ml) moderate immunolabeling of
Bergmann glia radial processes is also observed. Scale bars a 1 mm,
c 0.5 mm, b, d 50 lm. Modified from (Verrall et al. 2007). e,
f hDAAO and pLG72 subcellular localization. The subcellular
distribution of the two proteins has been investigated in U87
glioblastoma cells stably expressing EYFP-hDAAO and pLG72-
ECFP: e EYFP-hDAAO signal clearly overlaps with the stained
peroxisomal protein PMP70; f pLG72-ECFP fluorescence distribution
largely overlaps with the pattern of signal obtained by staining the
cells with a mitochondrial marker (Sacchi et al. 2011). Scale bars
3 lm
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localization of DAAO outside peroxisomes is mainly
related to interaction with regulatory interaction proteins
(see below).
Pathological aspects
Since D-serine-dependent, aberrant NMDAR activation is
involved in a variety of neurological diseases, a possible
imbalance in the levels or activities of the enzymes related to
the metabolism of this neuromodulator might be also
implicated. Multiple lines of evidence suggest that excessive
production or release of D-serine is involved in acute and
chronic degenerative disorders (stroke, epilepsy, amyotro-
phic lateral sclerosis (ALS), and Parkinson’s, Alzheimer’s,
and Huntington’s disease), while an anomalous drop in the
concentration of the neuromodulator can be observed in
psychiatric disorders such as schizophrenia and bipolar
disorders (Rossi et al. 2007; Labrie and Roder 2010; Mustafa
et al. 2010; Fuchs et al. 2011; Lu et al. 2011). In particular,
D-serine and SR levels are greatly increased in the spinal
cord of patients affected by familial and sporadic ALS as
well as in Alzheimer’s disease, while they are downregu-
lated in schizophrenia (Wolosker et al. 2008; Billard 2008
and references therein). Furthermore, it has been reported
that a unique mutation in the DAAO gene yielding an almost
total loss of enzymatic activity is associated with the adult
onset of familial ALS (Mitchell et al. 2010).
The molecular mechanisms thought to trigger NMDAR
hypofunction in schizophrenic patients have been investi-
gated. Genetic studies have identified several risk genes for
schizophrenia that influence NMDAR activity (Coyle
2006; Ross et al. 2006): these include genes that encode
proteins responsible for D-serine metabolism. Furthermore,
reduced levels of D-serine have been reported in the serum
and cerebrospinal fluid (CSF) of affected individuals
(Bendikov et al. 2007; Hashimoto et al. 2003) and, when
used as an adjuvant to both conventional neuroleptics (Tsai
et al. 1998) and new atypical antipsychotics (Heresco-Levy
et al. 2005), D-serine significantly improves the symptoms
of the disease. At present, there is weak evidence that the
D-serine-producing enzyme SR may be involved as a
schizophrenia susceptibility gene (Yamada et al. 2005;
Strohmaier et al. 2007) and that the protein expression
levels might be altered in forebrain areas of these patients
(Duplantier et al. 2009; Bendikov et al. 2007).
Since the landmark analysis of Chumakov et al. (2002)
was published in 2002, several association studies have
linked DAAO and its proposed regulatory interactor
pLG72 with schizophrenia susceptibility. pLG72 is a small
protein (153 amino acids, 18 kDa) with no recognizable
motifs and a high a-helix content, which suggests a
membrane localization (Fig. 3) (Molla et al. 2006b). It is
encoded by the G72 gene located within the chromosome
13q14 region, which provides significant genetic evidence
for linkage with the disease. G72 represents an exceptional
case of a primate-specific gene encoding for a rapidly
changing protein which is related to fast evolution of
underlying brain functions (Chen and Li 2001); Chumakov
et al. 2002). In brain, expression of pLG72 protein is
maximal in the midbrain and prefrontal cortex (Chumakov
et al. 2002; Korostishevsky et al. 2004), but the distribution
pattern is still controversial (Benzel et al. 2008). Early
studies on transiently transfected cells reported that pLG72
was localized in the endoplasmic reticulum/Golgi appara-
tus (Chumakov et al. 2002). More recently however, a
mitochondrial localization has been proposed for this pro-
tein (Otte et al. 2009; Sacchi et al. 2011). By means of a
yeast two-hybrid system, pLG72 was identified as a puta-
tive DAAO-interacting partner and it was suggested to
modulate the flavoenzyme activity (Chumakov et al. 2002).
Fig. 3 pLG72 properties deduced from its amino acidic sequence.
Secondary structure prediction was performed using Jpred server
(http://www.compbio.dundee.ac.uk/www-jpred/). Hydrophobicity plot
(arbitrary units) was calculated using Expasy ProtScale tool
(http://web.expasy.org/protscale/) and classical Kyte and Doolittle
parameters with a nine-residue window. Probability of disorder plot
(arbitrary units) was calculated using RONN software (http://www.
strubi.ox.ac.uk/RONN). Gray shaded areas represents hydrophobic
(top) or disordered (bottom) protein regions
Human D-amino acid oxidase 1837
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Notably, altered DAAO expression levels and activity
have been reported in schizophrenia patients. In particular,
DAAO activity was determined in postmortem brain tissues
from individuals who had been diagnosed as schizophrenia,
bipolar disorder, or major depressive disorder (Madeira
et al. 2008). Differently from the latter two conditions, an
increase in DAAO activity was demonstrated for the first
time in the cerebral cortex of schizophrenia patients, sug-
gesting that the enzyme is active in the forebrain areas
(regions particularly relevant for cognitive deficits) and
may play a role in the pathophysiology of the disorder.
Elevated DAAO activity in the cerebellum of affected
individuals (Kapoor et al. 2006; Burnet et al. 2008)
accompanied by an increase in gene expression was sub-
sequently reported (Verrall et al. 2007; Burnet et al. 2008).
In addition to the cerebellum, elevated DAAO immuno-
reactivity was also recently detected in the medulla
oblongata and choroid plexus (CP) (Ono et al. 2009) of
individuals affected by schizophrenia, suggesting that the
onset of the disease is associated with abnormal DAAO
levels in different brain areas. In particular, since CP plays
an important role in the homeostasis of nutrients (including
amino acids) in the CSF (Redzic and Segal 2004), the low
D-serine levels in the CSF of schizophrenia patients (Ha-
shimoto et al. 2003; Bendikov et al. 2007) might arise from
increased DAAO expression in the CP (Ono et al. 2009).
Increased DAAO activity in schizophrenia provides the
rationale to propose inhibition of D-serine-degrading
enzyme(s) (eventually in combination with D-serine
administration) as a therapeutic approach. Although no
clinical trials based on DAAO inhibitors to treat schizo-
phrenia have been performed to date, several preliminary
preclinical studies showed that DAAO inactivation (either
in ddY/DAAO-/- mice or after pharmacological inhibition
of the enzyme in rodents) produces behavioral, electro-
physiological, and neurochemical effects that suggest a
procognitive profile (Duplantier et al. 2009). However,
DAAO inhibitors to be used as drugs for therapeutic
treatments must be carefully designed since the mainte-
nance of the physiological balance between D-serine syn-
thesis and degradation appears extremely important. In
fact, the lack of degradation of the neuromodulator—as
observed in ALS affected individuals (Sasabe et al.
2012)—has been shown to induce motoneuron
degeneration.
Human DAAO biochemical properties
Over the past few decades, DAAO has become the para-
digm for the dehydrogenase/oxidase class of flavoproteins:
several aspects of the structural/functional relationships
have been extensively investigated using the protein
purified from pig kidney and the recombinant DAAOs from
microbial sources, mostly yeasts (Pollegioni et al. 1993,
2007a; Pilone 2000). The expression of human DAAO
(hDAAO) in E. coli was first reported in 2000 (Raibekas
et al. 2000), but this procedure yielded a low amount of
purified protein (0.5 mg l-1 culture medium). Most
recently, a robust and reliable process at the laboratory
bioreactor scale was established (Romano et al. 2009): this
procedure achieved *100 mg of hDAAO/liter culture
medium. Recombinant hDAAO was purified as a stable
and active holoenzyme (347 residues, *40 kDa), showing
the typical absorbance spectrum and properties of the
FAD-containing flavoenzymes (Molla et al. 2006a): (1)
hDAAO contains a single molecule of noncovalently
bound FAD per protein monomer; (2) hDAAO binds the
classical competitive inhibitors benzoate and anthranilate
(with Kd values in the lM range, see below); (3) the oxi-
dized flavin covalently binds sulfite; (4) the oxidized
cofactor is fully converted to the reduced species upon the
addition of a substrate under anaerobic conditions and then
quickly reacts with dioxygen; (5) the enzyme stabilizes the
anionic semiquinone form of the cofactor. The reaction
catalyzed by hDAAO follows a sequential kinetic mecha-
nism in which the rate-limiting step is represented by the
product release from the reoxidized enzyme, analogously
to porcine DAAO, although the rate of flavin reduction is
slower for the human enzyme (Molla et al. 2006a).
The human flavoprotein possesses a number of peculiar
properties. Since the binding of the flavin cofactor is the
weakest among the purified DAAOs (Kd = 8 9 10
-6 M,
40- and 400-fold higher than for the porcine and yeast
enzymes, respectively), the recombinant hDAAO exists in
solution as an equilibrium between the active holoenzyme
and the inactive apoprotein (Fig. 4). Indeed, a 20-fold
tighter interaction with FAD is observed when a ligand
(e.g., benzoate) is present in the active site of the enzyme
(Molla et al. 2006a). In the reconstitution process that leads
to the active holoenzyme, first the flavin cofactor binds to
the apoprotein (thus acquiring catalytic activity) and then a
slower secondary conformational change follows. The
latter is assumed to definitively stabilize the protein
(Caldinelli et al. 2009). hDAAO is a dimeric holoenzyme
in the 1- to 24-mg ml-1 protein concentration range which
retains this oligomeric state in the apoprotein form (Molla
et al. 2006a), whereas all known DAAO apoproteins are
stable 40-kDa monomers. Holo- and apoprotein forms of
hDAAO show substantial differences in conformation
while they share highly similar secondary structural
elements.
Likewise to other previously characterized DAAOs, the
human enzyme oxidizes small, uncharged D-amino acids. It
shows a low catalytic efficiency and substrate affinity on
the physiological substrate D-serine, whereas a higher
1838 S. Sacchi et al.
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activity is apparent on D-alanine (Table 1). Interestingly,
the human enzyme is also active on two additional sig-
naling molecules present at relevant concentrations in the
brain, i.e., the alternative NMDAR coagonist glycine and
the agonist of the receptor D-aspartate; however, the rela-
tive affinity for these substrates is very low (Table 1). In
contrast, no activity is evident on NMDA as substrate.
hDAAO shows a higher catalytic efficiency for bulky and
hydrophobic substrates, such as D-tryptophan, D-phenylal-
anine, D-tyrosine, and D-proline, and catalyzes the oxida-
tion of D-3,4-dihydroxy-phenylalanine (D-DOPA) into
dihydroxyphenylpyruvic acid (Kawazoe et al. 2007). It has
been proposed that D-DOPA might be pharmacologically
relevant since its L-stereoisomer is commonly used in the
treatment of Parkinson’s disease (human cells synthesize
dopamine from it). Interestingly, at low concentration
D-DOPA is metabolized more efficiently by hDAAO than
D-tyrosine and D-phenylalanine (stereoisomer of the dopa-
mine precursors) or any previously identified substrate
(Table 1); nevertheless, a substrate inhibition effect is
evident at high concentration (as also observed with
D-tyrosine and D-phenylalanine) (Kawazoe et al. 2007). As
L-DOPA is quickly converted to dopamine, the most
effective symptomatic treatment for Parkinson’s disease
Fig. 4 Scheme depicting the different forms of hDAAO observed in
vitro. Apoprotein (colorless in solution) is shown in gray; holoen-
zyme in yellow, and apoprotein–CPZ complex in pale yellow.
Substrate D-serine and inhibitor 3-hydroxyquinolin-2(1H)-one
(Duplantier et al. 2009) are shown in purple. Remarkably, hDAAO
is able to bind the substrate D-serine even in the apoprotein form
(Kd = 3.0 mM, not shown) (Caldinelli et al. 2010)
Table 1 Kinetic parameters of hDAAO on selected D-amino acids
kcat,app (s
-1) Km,app (mM) kcat,app/Km,app (s
-1 mM-1) References
D-Serine 3.0 ± 0.1 7.5 ± 0.5 0.4 Molla et al. (2006a)
D-Alanine 5.2 ± 0.1 1.3 ± 0.2 4 Molla et al. (2006a)
D-Proline 10.2 ± 0.1 8.5 ± 1.0 1.3 Molla et al. (2006a)
Glycine *0.9 *180 0.005 Molla et al. (2006a)
D-Aspartate *6.7 *2,000 0.003 Molla et al. (2006a)
D-Tryptophan 3.2 ± 0.1 1.5 ± 0.1 2.1 Molla et al. (2006a)
D-Phenylalanine 6.6 ± 0.1 2.7 ± 0.2 2.4 Molla et al. (2006a)
D-Tyrosine 14.8 1.5 9.9 Kawazoe et al. (2007)
D-DOPA 21.7 1.5 14.5 Kawazoe et al. (2007)
kcat,app and Km,app values were determined at air oxygen saturation (0.25 mM) and 25 C
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consists in administering it in combination with a periph-
eral DOPA decarboxylase inhibitor (Fernandez and Odin
2011). The slower utilization of D-DOPA and the longer
retention of its metabolites in the brain indicate that the
combination of the two isomers might represent a more
efficacious therapeutic strategy (Kawazoe et al. 2007).
More recently, DAAO was also reported to catalyze the
conversion of D-kynurenine (D-KYN) to kynurenic acid
(KYNA), a neuroactive metabolite of the kynurenine
pathway of tryptophan degradation with antioxidant prop-
erties (Lugo-Huitron et al. 2011). Although it was origi-
nally described as a broad spectrum antagonist of
excitatory amino acids receptors (Perkins and Stone 1982),
KYNA is known to inhibit the NMDAR (Ganong et al.
1983) through a preferential interaction with the D-Ser/Gly
coagonist site (Kessler et al. 1989). In addition, it acts as an
antagonist of the a7 nicotinic acetylcholine receptor and
also stimulates the orphan G-protein-coupled receptor
GPR-35. Recent investigations provided evidence that
DAAO may contribute to KYNA production by the oxi-
dative deamination of D-KYN in human and rat brain
(Fukushima et al. 2009; Ishii et al. 2010). In particular, (in
vivo) focal application of D-KYN by reverse microdialysis
induced a significant increase in extracellular KYNA levels
in the rat striatum and a concomitant reduction in extra-
cellular dopamine (Pe´rez-de la Cruz et al. 2012): pread-
ministration of a selective DAAO inhibitor markedly
suppressed the increase in extracellular KYNA (Fukushima
et al. 2009). Elevated KYN levels in mammalian tissues
might be a consequence of microbial infections. D-KYN
and DAAO may, therefore, be at least in part responsible
for the significant increases in brain KYNA levels seen
under inflammatory conditions (Holtze et al. 2008; Pe´rez-
de la Cruz et al. 2012).
Structural details of human DAAO (and functional
significance)
The overall three-dimensional structure of DAAO has been
largely conserved during evolution from microorganisms
(yeasts) to mammals (Pollegioni et al. 2002, 2007a, b); in
fact, the RMSD (root-mean-square deviation) between the
human and yeast (Rhodotorula gracilis) protein is only
1.48 A˚ (when superimposing the a-C of 228 residues), the
main differences being concentrated in a long C-terminal
loop. As expected, the structural similarity between porcine
(pkDAAO) and human enzyme is even higher, with a
RMSD of 0.40 A˚ when superimposing the a-C of 308
residues. DAAO tertiary structure can be divided in two
large domains formed by several noncontiguous sequence
regions (Fig. 5a): a FAD-binding domain possessing the
classical dinucleotide binding fold and an interface
(dimerization) domain characterized by a large twisted
antiparallel b-sheet formed by eight b-strands (Kawazoe
et al. 2006). Notwithstanding the conservation of the gen-
eral flavo-oxidase fold, relevant and specific structural and
functional differences are observed in the enzyme isolated
from different species (Pollegioni et al. 2007a).
Fig. 5 Ribbon representation of hDAAO in complex with 3-hy-
droxyquinolin-2(1H)-one (PDB code 3g3e) (Duplantier et al. 2009).
a Mode of hDAAO dimerization. The monomer on the left is
represented using a color scaling for temperature factors (or B-factor,
a parameter used to fit a potential structure to the electron density map
obtained from X-ray crystallography which measures the disorder of
the atoms in the structure): blue corresponds to a low and magenta to
a high B-factor values. b Detail of hDAAO active site. The inhibitor
is represented in brown and FAD cofactor in yellow. Hydrophobic
interactions are shown in pale yellow, H-bonds and polar interactions
are represented by black dotted lines, and p–p interactions are shown
by green arrows
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Dimerization
The quaternary structure of hDAAO in solution is always
dimeric, with a head-to-head mode of monomer–monomer
interaction (Fig. 5a). This is different from other mam-
malian DAAOs, which are either monomeric (e.g., DAAO
from rat, rDAAO) or show a concentration-dependent
oligomerization state (e.g., pkDAAO) (Pollegioni et al.
2007a; Frattini et al. 2011). The dimerization surface of
hDAAO is located at the top of the apical interface domain
and is formed by 36 residues: its composition was proposed
as the main determinant responsible for the different qua-
ternary structure observed in mammalian DAAOs. This
region is a hot spot for mutations with a substitution fre-
quency (33 %, 12 out of 36 residues) twofold higher than
for the remainder of the protein (13 %, 41 out of 311
residues). This results in a completely different distribution
of charges at the interface between the human and the
porcine enzyme: in pkDAAO, the dimerization interface is
mostly positively charged (Mattevi et al. 1996) while in the
human enzyme it is mainly negatively charged (Kawazoe
et al. 2006). Comparison of hDAAO with the closely
related monomeric rDAAO (80 % sequence identity)
(Frattini et al. 2011) shows that substitution of two of the
few positively charged residues at the hDAAO monomer–
monomer interface totally abolished the protein’s ability to
dimerize. These residues are His78 and, in particular,
Arg120, which is involved in electrostatic interactions with
the carboxylic group of Asp73 and hydrogen-bonded to the
backbone C = O groups of Asp109, Thr110, and Val111
(all belonging to the facing monomer). Interestingly,
hDAAO retains the dimeric state in the apoprotein form,
indicating that a large portion of the dimerization interface
is conserved even after FAD dissociation (Caldinelli et al.
2009).
FAD binding
The FAD cofactor is bound in an elongated conformation,
completely buried in the protein core (Fig. 5); the isoal-
loxazine ring is the sole part of the cofactor that is acces-
sible from bulk solvent. hDAAO binds FAD cofactor
mainly through the Rossmann fold of the FAD-binding
domain (N-terminal region of the protein). The complex
network of noncovalent contacts formed by the cofactor
with the protein moiety increases the stability of the protein
against chemical and thermal denaturation (see below)
(Caldinelli et al. 2009). Interestingly, comparative analysis
of the contact network between FAD and the surrounding
residues (within 6 A˚ from the cofactor) did not reveal
remarkable differences between human and porcine
DAAO, with the exception of a short hydrophobic stretch
(47-VAAGL-51) located close to the si-face of the flavin
isoalloxazine ring. This stretch is classified as a structurally
ambivalent peptide (SAP), i.e., a peptide that assumes
different conformations depending on the structural con-
text. In particular, the lower affinity for FAD to hDAAO
could arise from the loss of the H-bond between the
backbone nitrogen atom of Ala49 of SAP and flavin N(5):
the distance between these two atoms, which is 3.7 A˚ in
pkDAAO, is increased up to 4.9 A˚ in hDAAO. The loss of
the binding energy of a H-bond (*2 kcal mol-1) could
account for the 40-fold lower cofactor affinity (Gao and
Kelly 2008). In addition, the absence of the aforementioned
H-bond also correlated with the slower rate of flavin
reduction in hDAAO (180 s-1) as compared with the
porcine enzyme (4000 s-1) (Porter et al. 1977; Kawazoe
et al. 2006; Molla et al. 2006a).
The isoalloxazine ring, located at the interface between
the FAD binding and the interface domain, forms the
‘‘floor’’ of the active site (Fig. 5b). The protein residues
surrounding the isoalloxazine are fundamental for modu-
lating the functional properties of the cofactor (i.e., the
redox potentials). Two major interactions are observed in
this region: the first is an electrostatic interaction between
the flavin N(1) and the partial positive charge of a dipole,
generated by helix F5, which is assumed to stabilize the
negative charge of the reduced flavin during catalysis. The
second is a H-bond between FAD O(2) and Thr317
hydroxyl. This latter interaction is important both for
cofactor binding and function.
Substrate binding
The DAAO active site is striking in its simplicity, see
Fig. 5b (Umhau et al. 2000). DAAO catalyzes the transfer
of a hydride ion from the substrate to the N(5) atom: direct
participation of active-site residues is not required for the
chemical step of catalysis, e.g., there is no need for an
active-site base (Harris et al. 1999; Molla et al. 2000). The
main requirement favoring an efficient hydride transfer is a
very precise binding of the substrate relative to the FAD
cofactor (Umhau et al. 2000); in particular, the a-C of the
substrate must be at *3 A˚ from the N(5) of FAD with the
a-H pointing toward that atom. This condition is achieved
by formation of a tight network of H-bonds between the
substrate and the active-site residues. At the physiological
pH of the peroxisome (hDAAO main subcellular locali-
zation), the substrate amino acids are largely present in the
zwitterionic form (Harris et al. 2001). Hence, the nega-
tively charged oxygen atoms of the a-carboxylic group of
the substrate interact with the positively charged Arg283
and with the hydroxyl oxygen of Tyr228. The H-bonds
between the a-amino group of the substrate and FAD O(4)
and the Gly313 main chain C = O complete the bond
network. The substrate side chain points toward the inner/
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upper part of the active site that is formed by an array of
bulky hydrophobic residues (mainly Leu51, Leu215,
Tyr228, and Ile230). The van der Waals and hydrophobic
interactions formed in this region of the active site con-
tribute significantly to the overall binding energy of the
substrate and predispose the substrate specificity of the
enzyme to hydrophobic amino acids, Table 1. Remarkably,
Leu215 (Ile215 in pkDAAO) corresponds to Met213 of
yeast DAAO that was demonstrated to be the most
important residue for determining enzyme substrate spec-
ificity (Sacchi et al. 2002).
The volume of the human enzyme active site is
*220 A3, which is slightly larger than the pkDAAO active
site, whose volume is *160 A3 and thus suitable to
accommodate D-amino acids composed of up to nine heavy
atoms (e.g., D-valine possesses a volume of *170 A3)
(Mattevi et al. 1996). The roof of the active site of hDAAO
is formed by the side chain of Tyr224 (Fig. 5b), which is
not necessary for catalysis (Mattevi et al. 1996; Pollegioni
et al. 2007a). This residue belongs to loop 216–228, which
is thought to switch from an open to a closed conformation
upon substrate binding. In yeast DAAO, this loop is
replaced by a single side chain (Tyr238) (Pollegioni et al.
2002). The conformational movement of such an active-
site loop limits the turnover number of mammalian
DAAOs as compared to the yeast counterparts (14.7 and
350 s-1, respectively) and increases the hydrophobicity of
the active site, thus improving the efficiency of the hydride
transfer reaction. The flexibility of loop 216–228, and in
particular of the side chain of Tyr224, allows hDAAO to
bind substrates possessing large side chains, such as D-Phe,
D-Tyr, or even D-DOPA, as compared to its putative
physiological substrate D-serine (Table 1) (Molla et al.
2006a; Kawazoe et al. 2007).
Inhibitor binding
Classical DAAO inhibitors, such as benzoate, have been
known since the 1960s, see below (Fonda and Anderson
1968), but recently the discovery that DAAO and D-amino
acids are implicated in several physiological (and patho-
logical) processes in mammalian CNS prompted a quest for
more effective hDAAO inhibitors that potentially could be
employed as drugs. The combined use of structural bioin-
formatics (in particular virtual screening procedures based
on automated docking analysis), high-throughput screen-
ing, and structural biochemistry studies discovered several
high-affinity DAAO inhibitors and experimentally deter-
mined the structure of six different hDAAO-inhibitor
complexes (Table 2). These compounds can be subdivided
into three distinct chemotypes (Lange et al. 2011): (1) the
hetero(bi)cyclic carboxylic acids, as 5-methylpyrazole-3-
carboxylic acid (AS057278) (IC50 = 910 nM) (Adage
et al. 2008), 4H-furo[3,2-b]pyrrole-5-carboxylic acid
(IC50 = 141 nM) (Sparey et al. 2008), and 4H-thieno[3,2-
b]pyrrole-5-carboxylic acid (IC50 = 145 nM) (Smith et al.
2009); (2) a series of compounds based on benzo[d]iso-
xazol-3-ol, the most potent of which was 6-chloro-
benzo[d]isoxazol-3-ol (CBIO) (IC50 = 188 nM) (Ferraris
et al. 2008); and (3) the very potent hDAAO inhibitor
3-hydroxyquinoline-2-(1H)-one (IC50 = 4 nM) and its
analogs (Table 2) (Duplantier et al. 2009). Their main
properties and pharmacokinetics have been reviewed
recently (Sacchi et al. 2012).
From the huge amount of structural data, we were able
to elucidate in detail the binding mode of inhibitors at the
hDAAO active site (Table 2; Fig. 5b). hDAAO inhibitors
mimic D-amino acid binding behavior, i.e., the ligand
molecule can be divided into two functional regions: a first
region comprising polar or charged groups (e.g., a car-
boxylic acid, an hydroxyl, or an isoxazole ring) able to
form H-bonds with polar residues of the active site
(Arg283, Tyr228 and Gly313 main chain C = O, see
above) and a second hydrophobic region (usually formed
by a six- or five-atom aryl ring) which forms close contacts
with hydrophobic residues of the active site (Fig. 5b).
These hydrophobic interactions are of utmost importance
since the inhibitors (the only exception being the classical
ligand o-aminobenzoate) usually lack the substrate
a-amino group. In addition, the aromatic ring of the inhibitor
is stacked between the aryl ring of Tyr224 and the isoal-
loxazine ring of FAD (Ferraris et al. 2008), establishing
strong p–p interactions (Fig. 5b). In silico simulations
demonstrated that the best p–p interaction (in terms of
binding energy) is achieved when the aromatic rings are
not perfectly stacked (parallel-displaced configuration),
with an estimated value of 2.8 kcal mol-1 for each
p-stacking (Sinnokrot et al. 2002). This is true for the
hDAAO inhibitors showing the highest affinities (i.e.,
3-hydroxyquinoline-2(1H)-one or inhibitors with a fused
pyrrole carboxylic acid) as compared to benzoate or
o-aminobenzoate where an almost perfect superimposition
between Tyr244 and the aromatic ring of the inhibitor is
observed (Sparey et al. 2008; Duplantier et al. 2009). In
some cases, both the overall molecular volume and the
hydrophobicity of the inhibitor are enhanced by adding a
halogen substituent to the aromatic ring, e.g., chlorine in
CBIO (Ferraris et al. 2008) or chlorine or fluorine in
compounds listed in Duplantier et al. (2009). Unfortu-
nately, the results of such additions are unpredictable since,
in several cases, large decreases in affinity were observed,
probably because of steric clashes between the halogen
substituent and the protein moiety (Duplantier et al. 2009).
Concerning the size of the inhibitor, hDAAO possesses
a large active-site plasticity: the best inhibitors are com-
posed of more than nine atoms and the presence of the
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aromatic ring renders them quite compact. In fact, the best
inhibitor, 3-hydroxyquinoline-2(1H)-one, is formed by 12
atoms (and a volume of 149 A3) and it fits easily into the
active site of the enzyme (Table 2).
Modulation of hDAAO structural–functional properties
In vitro studies
The conformation, function, and stability of hDAAO are
affected by interactions with several partners: small-size
molecules (FAD, substrates, and inhibitors) and interacting
proteins.
FAD cofactor, mandatory for enzyme activity, is only
weakly bound to hDAAO apoprotein (Kd = 8 lM) (Molla
et al. 2006a). By associating FAD to the apoprotein moiety,
a holoenzyme is generated that possesses a more ‘‘com-
pact’’ tertiary structure, decreased exposure of hydrophobic
surfaces, and lower sensitivity to proteolysis and thermal
denaturation (Table 3) (Caldinelli et al. 2009).
The classical competitive inhibitor benzoate (Kd = 7
lM, Ki = 7 lM) (Molla et al. 2006a; Kawazoe et al. 2006)
binds to the hDAAO active site, yielding a *20-fold
increase in affinity for the cofactor (Kd = 0.3 lM, Fig. 4)
(Molla et al. 2006a). This raises the amount of the holo-
enzyme formed in solution and protects hDAAO against
proteolysis and thermal denaturation (a Tm increase of
*5 C was apparent in the presence of benzoate, Table 3)
(Caldinelli et al. 2010). Similar effects were observed in
the presence of the pseudosubstrate CF3-D-alanine
(Ki = 3 lM), which also binds to hDAAO apoprotein and
increases the Kd for FAD binding (Caldinelli et al. 2010).
Another well-known hDAAO inhibitor is chlorproma-
zine (CPZ), a drug widely employed for the treatment of
schizophrenia. CPZ competes with FAD for the binding to
hDAAO apoprotein (Kd = 5 lM; Ki = 0.7 mM, Table 2)
(Sacchi et al. 2008; Iwana et al. 2008). When in complex
with CPZ, hDAAO is supposed to assume a conformation
resembling that of the apoprotein since it is more sensitive
to proteolysis and thermal denaturation than the native
holoenzyme (Table 3; Fig. 4) (Caldinelli et al. 2010).
Concerning the modulation of hDAAO function by
protein partners, pLG72 was identified by a yeast two-
hybrid approach as a putative interacting partner of mam-
malian DAAOs (Chumakov et al. 2002). Subsequently, in
slices from human brain cortex, we identified hDAAO and
pLG72 in the same astrocytes and reported on the coim-
munoprecipitation of the two proteins from human cortex
extracts. We also demonstrated that pLG72 binding to both
the holo- and apoprotein forms of hDAAO yields an
*200-kDa complex constituted by two hDAAO homodi-
mers (2 9 80 kDa) and two pLG72 molecules (2 9
20 kDa) (Sacchi et al. 2008). Real-time analysis by the
SPR method of the interaction between the holoenzyme or
the apoprotein species of hDAAO to immobilized pLG72
showed similar apparent affinities (Kd values were 5.3 vs.
3.1 9 10-7 M with and without free FAD, respectively)
(Caldinelli et al. 2010). By using hDAAO-immobilized
sensors and flushing different concentrations of pLG72, the
association rate constants were higher than those with
immobilized pLG72 (and traces were not affected by the
presence of FAD): Kd value was 0.8 9 10
-7 M.
pLG72 binding does not affect the kinetic parameters
of the reaction catalyzed by hDAAO on D-serine, the
affinity for the cofactor, and the rate constant of FAD
binding to the apoprotein: the main effect is a faster time
course of hDAAO inactivation (Sacchi et al. 2008). We
demonstrated that pLG72 binding modifies hDAAO ter-
tiary structure and produces a decrease in the holoenzyme
(active) form. In fact, the amount of FAD cofactor bound
to the enzyme that can be reduced by the substrate
decreases after the pLG72-hDAAO complex is formed.
Visible absorbance and near-UV CD spectroscopy also
show that pLG72 binding altered the tertiary structure of
hDAAO. Indeed, limited proteolysis studies show that the
presence of a stoichiometric amount of pLG72 increases
the rate of hDAAO holoenzyme degradation (Fig. 6a), a
destabilization most apparent at increasing pLG72 con-
centrations, see (Caldinelli et al. 2010). In contrast, the
time course of proteolysis of the apoprotein form is not
affected by adding pLG72 (Fig. 6a) (Caldinelli et al.
2010). The destabilization effect of pLG72 interaction on
hDAAO half-life was also apparent at the cellular level
(see below). Taken together, we propose that pLG72
binding switches off hDAAO activity and, under normal
conditions, prevents glial D-serine from being fully
degraded (Fig. 1b).
None of the small ligands tested (FAD, benzoate,
D-serine, or CPZ) modified the hDAAO-pLG72 complex
formation, as judged by SPR and gel permeation analyses.
Binding of FAD, benzoate, and CF3-D-alanine counteracts
the destabilizing effect of pLG72, while CPZ binding
further increases susceptibility to proteolysis (Caldinelli
et al. 2010).
Table 3 Effect of ligand binding on the thermostability (Tm values)
of hDAAO as determined by protein fluorescence (Caldinelli et al.
2010)
Temperature-induced unfolding (Tm, C)
?FAD ?CPZ
Free form 50.1 ± 1.7 51.8 ± 0.2 48.0 ± 0.7
Benzoate complex 55.2 ± 0.2 55.4 ± 0.2
CF3-D-Ala complex 54.7 ± 0.2 55.7 ± 0.2
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Cellular studies
We recently tried to resolve the apparent discrepancy in
subcellular localization of hDAAO and pLG72. In fact,
DAAO is a well-known peroxisomal enzyme (see above
and Fig. 2e) while pLG72 has been reported to be a
mitochondrial protein for COS7-transfected cells, glioma
U251, and primary neurons (Benzel et al. 2008; Kvajo
et al. 2008). However, in human cultured astrocytes it
showed a perinuclear and tubular distribution (Sacchi et al.
2008). Since only 5 % of the latter cells displayed (cyto-
solic) overlapping signals for pLG72 and hDAAO, with a
mean average of 8 % colocalization, we proposed that
pLG72 interaction with hDAAO is probably driven by
specific, unknown spatiotemporal stimuli (Sacchi et al.
2008). Recently, by means of immunohistochemistry and
organelle immunoprecipitation, we have confirmed that
pLG72 has a mitochondrial localization in U87 glioblas-
toma cells (Fig. 2f) (Sacchi et al. 2011). By using U87 cells
stably expressing pLG72-ECFP and transiently transfected
with EYFP-hDAAO, we demonstrated that colocalization
is most apparent at 24 h after hDAAO transfection, when
the fluorescence signal corresponding to the flavoenzyme is
largely diffused in cytosol and the associated FRET signal
shows a distribution pattern resembling the one typically
associated with mitochondria (and pLG72). Indeed, at 24 h
from transfection the amount of hDAAO in the membrane-
bound fraction is higher in cells overexpressing pLG72
than in U87 control cells, suggesting sequestration of
newly synthesized hDAAO on the surface of mitochondria
owing to the interaction with pLG72. The pLG72-hDAAO
colocalization, as well as the FRET signal, was progres-
sively lost for longer periods, which was paralleled by the
appearance of a punctuate distribution of hDAAO, indi-
cating that it was correctly targeted to peroxisomes. Indeed,
subcellular fractionation analysis demonstrated that cyto-
solic hDAAO is active and its specific activity resembles
that of the peroxisomal enzyme (Sacchi et al. 2011).
Binding of hDAAO to pLG72—probably located on the
cytosolic side of mitochondrial membranes—and ensuing
enzyme inactivation and faster degradation plays a pro-
tective role against DAAO-induced depletion of cytosolic
D-serine and also helps to prevent cellular oxidative stress.
The relationship between pLG72, hDAAO, and the
cellular concentration of D-serine was assessed using
human glioblastoma U87 cells transfected with pEGFP-C3
expression vectors encoding for EGFP-hDAAO and/or
EGFP-pLG72 proteins and HPLC analyses to measure
D- and L-serine concentrations (Sacchi et al. 2008). The D-/
L-serine ratio determined on control cells decreased in the
cells transfected with the plasmid encoding for hDAAO but
did not show a statistically significant change in those
transfected with the plasmid for pLG72 and in the cells
cotransfected with the two plasmids. Similarly, hDAAO
activity increased in U87 cells transfected with the pEGFP-
hDAAO plasmid (Sacchi et al. 2008). The time course of
D-serine concentration following hDAAO transient
Fig. 6 pLG72 modulates hDAAO stability/activity and cellular
D-serine levels. a The time course of trypsin digestion of hDAAO
(holo- and apo-form) is compared to that obtained for the hDAAO-
pLG72 complex. As observed by monitoring the 40-kDa band
corresponding to the intact monomer (top panel) by SDS-PAGE and
densitometric analysis (bottom panel), binding of pLG72 to the
holoenzyme produces an increase in hDAAO sensitivity to proteolytic
degradation; no significant change in protein stability is apparent for
the apoprotein form. The intensity of the 40-kDa band of the sample
before adding trypsin (sample 0, top panel) is indicated as 100 %.
Open square in bottom panels represent hDAAO-pLG72 complex,
while closed circle represent the free hDAAO form. b D-Serine/L-
serine concentration ratio determined by HPLC analysis on cell
extracts from U87 and U87 pLG72-ECFP cells transiently transfected
with EYFP-hDAAO. The measured values are higher in the cells
stably expressing pLG72, thus confirming the negative effect exerted
by pLG72 on hDAAO stability/activity. Errors bars represent the
standard error; *p \ 0.001, **p \ 0.0001 (Sacchi et al. 2011)
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expression is different in U87 controls versus U87 pLG72-
ECFP cells, as is the D-serine concentration at 24 h
(Fig. 6b): the binding of pLG72 to newly synthesized
hDAAO switches off the flavooxidase activity and limits
the decrease in D-serine concentration.
Concerning the effect of small-size ligands, both benzoate
and CPZ yield a statistically significant increase in
D/(D ? L)-serine concentration ratio in U87 cells stably
transfected with hDAAO as compared to untreated controls
(Caldinelli et al. 2010). Furthermore, CPZ treatment yields a
statistically significant decrease in hDAAO cellular levels
48 h later. When the same experiment was carried out using
U87 glioblastoma cells stably expressing EGFP-hDAAO
and transiently expressing pLG72, CPZ treatment signifi-
cantly decreased the amount of active hDAAO while ben-
zoate slightly increased the cellular hDAAO in cotransfected
cells. Both compounds increased the cellular D-serine con-
centration (because of hDAAO inhibition) but, intriguingly,
using a different strategy for hDAAO inhibition (substrate
vs. cofactor competition) might affect the in vivo concen-
tration of D-serine to a different extent because protein sta-
bility is modulated dissimilarly (Caldinelli et al. 2010).
Recently, 24 putative DAAO-interacting proteins were
identified by immunoprecipitation from rat cerebellar
lysates using an anti-rDAAO antibody (Popiolek et al.
2011). Interestingly, the most robust interaction occurred
with bassoon (BSN) and piccolo (PCLO), two components
of the presynaptic active zone (Garner et al. 2000), a spe-
cialized subcellular domain where synaptic vesicles are
docked and primed before they fuse to the membrane and
release their neurotransmitter content (Owald and Sigrist
2009). Since the D-serine/D-alanine transporter Asc-1 is
also enriched at the presynaptic terminus, the presence of
extraperoxisomal DAAO suggests that some of the read-
sorbed D-serine/D-alanine may be metabolized, further fine-
tuning their concentration at the synapse and consequently
affecting NMDAR activation (Popiolek et al. 2011). Fur-
thermore, BSN overexpression (HEK293 cell line stably
expressing rDAAO and transiently transfected for BSN)
decreased DAAO enzymatic activity by 30 %.
Evolution of human DAAO properties
DAAO represents a clear example of promiscuity, i.e. the
enzyme shows the ability to act on different substrates and,
for this reason, to be involved in different biochemical
pathways. Owing to this property DAAO can play different
physiological roles (Pollegioni et al. 2007a, see ‘‘Intro-
duction’’). The high versatility of this enzyme implies that
specific structural features (confined to restricted regions
since they do not modify the overall folding of the protein)
related to the different specific roles have been acquired/
altered during evolution. In particular, the role of DAAO in
human brain requires a different substrate specificity and
slower turnover than yeast DAAO. These features were
gained because of the presence of the large lid loop cov-
ering the active-site entrance in mammalian DAAOs. In
this step, the loop of hDAAO (which function is partially
played by the side chain of Tyr238 in yeast DAAO)
(Pollegioni et al. 2002) limits the rate of product release
during catalysis and slows D-serine oxidation (Molla et al.
2006a). In addition, a second mechanism to control the
enzyme activity evolved to prevent excessive degradation
of local D-serine. In yeast DAAO, FAD cofactor is bound
with a high affinity, it is necessary for protein dimerization,
and it plays a fundamental role in stabilizing the enzyme
against chemical and thermal denaturation. On the other
hand, FAD interaction with the hDAAO apoprotein moiety
is weak and its binding does not alter the dimeric quater-
nary structure of the protein (Pollegioni et al. 2007a;
Caldinelli et al. 2009). Accordingly, hDAAO is present in
solution as a mixture of the (active) holoenzyme and the
corresponding (inactive) apoprotein. Indeed, in the pres-
ence of a substrate (analog) the interaction between FAD
and the hDAAO apoprotein moiety is 20-fold tighter and
induces a ‘‘more packed’’ protein structure due to specific,
induced conformational changes (Fig. 4).
From a physiological point of view, the weak interaction
with FAD, together with the low affinity for the substrates,
may have represented an evolutionary strategy to produce
an enzyme that might be largely present in an active form
only in the presence of high concentrations of D-serine. In
fact, considering the physiological concentration of both
FAD and D-serine in brain tissues in vivo, hDAAO should
normally be present in the inactive apoprotein form. It is
tempting to speculate that the low affinity of hDAAO for
the cofactor has been selected to control D-serine concen-
tration in brain so as to avoid excessive degradation. On the
other hand, elevated levels of hDAAO activity (as in
pathological conditions) presumably enhance D-serine
catabolism, consequently affecting the release of the sig-
naling molecule and its availability at synapse and thus
potentially impairing NMDAR function (Fig. 1b). In this
respect different lines of evidence indicate that hDAAO is
involved in the NMDAR hypofunction observed in
schizophrenia. Furthermore, loss of hDAAO activity and
the consequent increase in D-serine levels has been shown
to trigger motoneuron degeneration and to be relevant in
ALS (Sasabe et al. 2007).
Concluding remarks
Maintaining physiological concentrations of D-serine, and
thus the fine balance between synthesis and degradation, is
1846 S. Sacchi et al.
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crucial for the brain to develop and function correctly. For
this reason, the structural/functional properties of hDAAO
and the factors (effector molecules and regulatory inter-
acting proteins) affecting its functionality should be
investigated in greater depth. It is of uttermost importance
to clarify the complex processes that are in play in D-serine
metabolism, which we aimed to do in this review. This will
help in designing new and more effective drugs for the
treatment of the different pathological conditions in which
NMDAR dysfunction is implicated.
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